Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 311 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Overweight Subjects Clear all

Conditions: Obesity
Interventions: Placebo, CP-945,598, CP-945,598 Treatment B; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 975 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 43
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 37 more

Conditions: Healthy Volunteer
Interventions: ABBV-295, Placebo for ABBV-295; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Obesity
Interventions: Naltrexone SR 32 mg/bupropion SR 360 mg/day, Placebo, fMRI scan; Drug · Other
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Upton, New York

Conditions: Back Pain
Interventions: thermal therapy, ThermaCare heatwrap; Device
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Obesity, Metabolic Syndrome X
Interventions: Metformin, Orlistat, Topiramate, Placebo; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 40 Years to 75 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: HIV Infection, Diabetes Mellitus Type 2, Obesity, Overweight, Metabolic Syndrome
Interventions: Liraglutide; Drug
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obesity
Interventions: Zonisamide SR placebo/ bupropion SR placebo, Zonisamide SR placebo/ bupropion SR 360 mg/day, Zonisamide SR 120 mg/day/ bupropion SR placebo, Zonisamide SR 360 mg/day/ bupropion SR placebo, Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day, Zonisamide SR 360 mg/day/ bupropion SR 360 mg/day; Drug
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 20
States / cities: Fairhope, Alabama • La Jolla, California • Denver, Colorado + 17 more

Conditions: Non-diabetic Overweight or Obese
Interventions: Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week., Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week., Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.; Drug
Lead sponsor: BrightGene Bio-Medical Technology Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obesity, Overweight
Interventions: Oral semaglutide, Placebo (semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 667 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • Kissimmee, Florida + 10 more

Conditions: Obesity, Cardiovascular Diseases
Interventions: Naltrexone HCl/Bupropion HCl ER, Placebo; Drug
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 139
States / cities: Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 136 more

Conditions: Overweight, Obesity
Interventions: AMG 133; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 3
States / cities: Anaheim, California • Los Alamitos, California • Dallas, Texas

Conditions: Overweight or Obesity, Type2 Diabetes Mellitus
Interventions: GSBR-1290, Placebo; Drug
Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Anaheim, California • Chula Vista, California • Miami, Florida + 1 more

Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: ALT-801, Placebo; Drug · Other
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 15
States / cities: Scottsdale, Arizona • Tucson, Arizona • Montclair, California + 9 more

Conditions: Obesity
Interventions: maridebart cafraglutide, Placebo; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Anaheim, California • Tustin, California • Miami, Florida

Conditions: Overweight, Obesity
Interventions: pramlintide acetate 360 mcg, metreleptin, placebo-pramlintide 600 uL, placebo-metreleptin 1 mL, Pramlintide acetate 180 mcg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 12
States / cities: DeLand, Florida • Chicago, Illinois • Indianapolis, Indiana + 9 more

Conditions: Obesity
Interventions: CP-741,952; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Ann Arbor, Michigan • Kalamazoo, Michigan • New York, New York + 2 more

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: NNC9204-0530, liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 163 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Cardiac Surgery, Sternal Wound Infection
Interventions: gentamicin-collagen sponge dipped in saline; Drug
Lead sponsor: Innocoll; Industry
Eligibility: 18 Years and older
Enrollment: 1,502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 43
States / cities: Birmingham, Alabama • Florence, Alabama • Pasadena, California + 39 more

Conditions: Obesity
Interventions: LIK066, Carbohydrate 50%, Carbohydrate 25%, Carbohydrate 8%, Carbohydrate 0%, Psyllium, Calcium carbonate; Drug · Dietary Supplement
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Overweight, Diabetes, PreDiabetes, Obesity
Interventions: Gelesis200, Placebo; Device
Lead sponsor: Gelesis, Inc.; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 12
States / cities: Birmingham, Alabama • Bradenton, Florida • Miami, Florida + 9 more

Conditions: Obesity
Interventions: Release Supplement, Placebo; Dietary Supplement
Lead sponsor: Golo; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Valparaiso, Indiana

Conditions: Obesity, Hepatic Insufficiency
Interventions: CP-945,598; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Obesity
Interventions: group sessions, sibutramine, orlistat, diethylpropion, Low Calorie Diet, Health One, Intensive Medical Combination Therapy for Obesity, Control Condition; Behavioral · Drug · Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 20 Years to 60 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Type 2 Diabetes Mellitus
Interventions: GSK376501, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Evansville, Indiana

Search by objective public record fields.

A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients

A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.

A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects

Heat Wrap Device Safety With Age and Body Fat

Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity

Liraglutide for HIV-associated Neurocognitive Disorder

Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects

Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)

Naltrexone/Bupropion Cardiovascular Outcomes Study

A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity

Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity

A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects

Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity

Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects

Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection

Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066

Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects w/o Type 2 Diabetes

Effects of the GOLO Weight Management Program With and Without Release Supplement on Weight and Metabolic Parameters in Subjects With Obesity

Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug

LOSS- Louisiana Obese Subjects Study

Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects